Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Guangxi
-
Nanning, Guangxi, China
- Guangxi Centers for Disease Control and Prevention
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female freshmen in one college in Liuzhou city of Guangxi Zhuang Autonomous Region
Exclusion Criteria for vaccination study:
- acute illness
- immunocompromised conditions
- renal insufficiency
- pregnancy
- allergic history to HB vaccine or yeast
- positive for any of HBsAg, anti-HBs or anti-HBc
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: HBV vaccine
HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Anti-HBs immune response in participants negative for HB sAg, anti-HBs and anti-HBc
Time Frame: Anti-HBs was assayed at Month 7
|
Anti-HBs was assayed at Month 7
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Seroprevalence for HBsAg, anti-HBs and anti-HBc in Chinese college students
Time Frame: seroprevalence at baseline
|
seroprevalence at baseline
|
|
Anti-HBs immune response in participants negative for HBsAg, anti-HBs and anti-HBc
Time Frame: Anti-HBs immune response at Month 1
|
Anti-HBs immune response at Month 1
|
|
Anti-HBs immune response in participants negative for HBsAg, anti-HBs and anti-HBc
Time Frame: Anti-HBs immune response at Month 6
|
Anti-HBs immune response at Month 6
|
|
Anti-HBs immune response in participants negative for HBsAg, anti-HBs and anti-HBc
Time Frame: Anti-HBs immune response at Month 20
|
Anti-HBs immune response at Month 20
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PRO-HBV-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.